Organicell Regenerative Medicine, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of biological therapeutics for the treatment of degenerative diseases and to provide other related services. RAAM products are used in the healthcare industry administered through doctors and clinics. Its leading product, Zofin (Organicell Flow), is an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent. The product contains over 300 growth factors, cytokines, chemokines, and 102 unique microRNAs as well as other exosomes derived from perinatal tissues. It has obtained certain Investigation New Drug (IND), and emergency IND (eIND) approvals from the United States Food and Drug Administration (FDA), including applicable Institutional Review Board (IRB) approvals which authorized the Company to commence clinical trials.
|Moving Averages||Neutral||Buy||Sell||Strong Sell||Strong Sell|
|Technical Indicators||Buy||Strong Buy||Buy||Strong Sell||Strong Sell|
|Summary||Neutral||Strong Buy||Neutral||Strong Sell||Strong Sell|